var data={"title":"Pathogenesis of AA amyloidosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis of AA amyloidosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/contributors\" class=\"contributor contributor_credentials\">Peter D Gorevic, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/contributors\" class=\"contributor contributor_credentials\">Helen J Lachmann, MA, MB, BChir, MD, FRCP, FRCPath</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/contributors\" class=\"contributor contributor_credentials\">Paul L Romain, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 04, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant. Amyloidosis encompasses a group of diseases caused by misfolding and extracellular accumulation of proteins as fibrillar deposits. These fibrils stain with Congo red and produce pathognomonic green birefringence when viewed by microscopy under crossed polarized light. The process of amyloid formation and deposition causes tissue toxicity and progressive organ dysfunction.</p><p>The pathogenesis of AA amyloidosis is presented here. The clinical manifestations, diagnosis, and treatment of this disorder, an overview of amyloidosis, and the pathogenesis of other forms of amyloidosis are discussed separately. (See <a href=\"topic.htm?path=causes-and-diagnosis-of-aa-amyloidosis-and-relation-to-rheumatic-diseases\" class=\"medical medical_review\">&quot;Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases&quot;</a> and <a href=\"topic.htm?path=treatment-of-aa-secondary-amyloidosis\" class=\"medical medical_review\">&quot;Treatment of AA (secondary) amyloidosis&quot;</a> and <a href=\"topic.htm?path=overview-of-amyloidosis\" class=\"medical medical_review\">&quot;Overview of amyloidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2391684817\"><span class=\"h1\">AMYLOID PRECURSORS AND AMYLOIDOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All forms of amyloidosis, including AA amyloidosis, are characterized by codeposition of other molecules, including [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum amyloid P component (SAP), a member of the pentraxin family that includes C-reactive protein</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Glycosaminoglycans, notably heparan sulfate</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Apolipoproteins (E and J)</p><p/><p>There are 34 different human precursor proteins known to be deposited in a fibrillar configuration as amyloid [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/3\" class=\"abstract_t\">3</a>]. Common examples include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum amyloid A (SAA) protein in AA amyloidosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monoclonal immunoglobulin light chains in primary or immunoglobulin light chain (AL) amyloidosis (see <a href=\"topic.htm?path=pathogenesis-of-immunoglobulin-light-chain-al-amyloidosis-and-light-and-heavy-chain-deposition-diseases\" class=\"medical medical_review\">&quot;Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta-2 microglobulin in dialysis-related amyloidosis (see <a href=\"topic.htm?path=dialysis-related-amyloidosis\" class=\"medical medical_review\">&quot;Dialysis-related amyloidosis&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transthyretin in wild-type transthyretin (TTR) amyloidosis (previously known as senile cardiac amyloidosis)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Several different apolipoproteins among the hereditary amyloidoses (see <a href=\"topic.htm?path=genetic-factors-in-the-amyloid-diseases\" class=\"medical medical_review\">&quot;Genetic factors in the amyloid diseases&quot;</a>)</p><p/><p>A number of factors have been identified that contribute to the pathogenesis of AA amyloid:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sustained increase in the serum concentration of SAA in chronic inflammatory states</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Posttranslational modifications that may influence synthesis or destabilize SAA and favor its misfolding and aggregation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interruption of ligand binding to various receptors as a result of proteolysis at position 76 of SAA [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/4\" class=\"abstract_t\">4</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The intrinsic propensity of SAA subsequences to misfolding</p><p/><p>A combination of these factors may determine the amyloidogenicity. Nonetheless, undetermined environmental and genetic factors must also be involved as only a minority of patients with sustained inflammation and persistent elevation of SAA levels develop AA amyloidosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Cofactors, such as glycosaminoglycans and SAP, may play a role in predisposition to amyloid formation via one or more of the following effects [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/2,6-9\" class=\"abstract_t\">2,6-9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Modulation of fibrillogenesis by direct binding to specific domains of subunit proteins or their precursors</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stabilization of the fibril and protection from degradation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Localization to specific organs or tissue sites by binding to matrix components or receptor molecules</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Secondary effects on the metabolism of precursor protein, leading to the accumulation of degradation products with amyloidogenic potential</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Modulation of proteolytic events that may facilitate fibril formation</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">SERUM AMYLOID A PROTEIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=acute-phase-reactants\" class=\"medical medical_review\">&quot;Acute phase reactants&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Types</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several forms of SAA have been identified in serum. These include acute phase (SAA1 and SAA2) and constitutive (SAA4) isoforms, allelic variants, and posttranslational modifications of these gene products [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/1,10\" class=\"abstract_t\">1,10</a>]. Acute phase SAA proteins (SAA1 and SAA2) are apolipoproteins, primarily associated with specific high-density lipoprotein (HDL), and are also expressed extrahepatically (eg, synovial membrane) in the absence of HDL [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Expression of SAA1 and SAA2 is induced by a number of factors, particularly interleukin (IL)-6, but also IL-1, tumor necrosis factor (TNF), lipopolysaccharide (LPS), and several transcription factors, notably including SAA-activating factor (SAF)-1 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SAA1 is the precursor protein in most individuals with AA amyloid [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Binding of heparin to SAA1 displaces it from HDL, perhaps contributing to the mechanism by which heparin and heparan sulfate facilitate formation of AA amyloid [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SAA1 has three alleles, designated SAA1.1, SAA1.3, and SAA1.5, defined by amino acid substitutions at positions 52 and 57 of the molecule [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The frequency of these alleles varies between populations and homozygosity for SAA1. SAA1 has been associated with an increased risk of AA amyloidosis in diseases such as rheumatoid arthritis and familial Mediterranean fever in Caucasians, perhaps because of increased susceptibility to proteolytic cleavage by specific metalloproteinases [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/17,18\" class=\"abstract_t\">17,18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the Japanese, specific single nucleotide polymorphisms (SNPs) of the gene for SAA1.3 have been associated with increased gene transcription, AA amyloidosis complicating rheumatoid arthritis, and susceptibility to familial Mediterranean fever [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Possible function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The acute phase response, as reflected in the <em>SAA</em> gene, has been conserved for half a billion years throughout vertebrate evolution. In humans, SAA is one of the most dynamic components with a potential increase in circulating concentration of more than 1000-fold, implying that it has important functions in the inflammatory response. Nonetheless, the exact contributions SAA proteins play in host defense remain somewhat opaque.</p><p>SAA proteins may increase the affinity of HDLs for macrophages and adipocytes during the acute phase response, a property termed &quot;reverse cholesterol metabolism&quot; [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/10,20,21\" class=\"abstract_t\">10,20,21</a>]. Other properties include extracellular matrix binding [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/22\" class=\"abstract_t\">22</a>]; opsonization of Gram-negative bacteria [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/23\" class=\"abstract_t\">23</a>]; chemoattractant activity for monocytes, neutrophils, and lymphocytes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/24\" class=\"abstract_t\">24</a>]; induction of the release of proinflammatory cytokines from neutrophils [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/25,26\" class=\"abstract_t\">25,26</a>]; and platelet effects [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/25,27\" class=\"abstract_t\">25,27</a>]. Pro- and antiinflammatory effects of SAA vary with regard to the blood pool of hepatically derived acute phase SAA; local effects of tissue- and macrophage-derived SAA; and whether SAA is bound to HDL or delipidated [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Ligands</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>SAA interacts specifically with a wide range of ligands, either bound to the surface of HDLs or in a lipid-free form. The former include cholesterol (residues 1 to 18 and 40 to 63 of SAA), HDL (residues 1 to 18), calcium (residues 48 to 51), laminin (residues 24 to 76), and <span class=\"nowrap\">heparin/heparan</span> sulfate (two binding sites within residues 17 to 49 and 77 to 103); the last ligand, in particular, has been targeted for the development of therapeutic agents for the treatment of AA amyloid [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=treatment-of-aa-secondary-amyloidosis\" class=\"medical medical_review\">&quot;Treatment of AA (secondary) amyloidosis&quot;</a>.)</p><p>Some SAA binding may occur selectively within the joint space of patients with rheumatoid arthritis, as both acute phase and constitutive isoforms of SAA appear to be synthesized by synovial tissue [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/11,30\" class=\"abstract_t\">11,30</a>]. High levels of both SAA and its receptor, formyl peptide receptor-like 1 (FPRL1), have been demonstrated in the rheumatoid synovium, and a link to leukocyte infiltration, including the influx of CCR6-expressing Th17 cells, was confirmed by the ability of SAA to upregulate CCR20 expression of rheumatoid arthritis synoviocytes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/31\" class=\"abstract_t\">31</a>]. Acute phase SAA may directly stimulate the production of TNF-alpha and acute phase pentraxin production by synoviocytes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/32\" class=\"abstract_t\">32</a>]; the acute phase SAA can mediate inflammatory and angiogenic effects by interaction with toll-like receptors (TLR2 and TLR4) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/28,33\" class=\"abstract_t\">28,33</a>]. Inhibition of IL-6-mediated induction of acute phase SAA in rheumatoid synovium by <span class=\"nowrap\">JAK/STAT</span> (Janus <span class=\"nowrap\">kinase/signal</span> transducer and activator of transcription) inhibitors being developed for clinical use provides another mechanism for abrogating SAA that may have potential for use in inflammatory arthritis, as well as in AA amyloidosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">PATHOGENESIS OF AA AMYLOIDOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Common causes of AA amyloidosis are rheumatoid arthritis, chronic infections (particularly in resource-limited countries), and autoinflammatory disorders [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/35,36\" class=\"abstract_t\">35,36</a>]. (See <a href=\"topic.htm?path=causes-and-diagnosis-of-aa-amyloidosis-and-relation-to-rheumatic-diseases\" class=\"medical medical_review\">&quot;Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases&quot;</a>.)</p><p>AA amyloid occurs in various mammalian and avian species and can be induced by chronic inflammatory stimuli. The best-studied model for this disease is amyloid induction by <span class=\"nowrap\">casein/azocasein</span> injections in certain genetically susceptible strains of mice [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/37\" class=\"abstract_t\">37</a>]. Although most animal models for AA amyloid parallel human disease with predominant fibril deposition in spleen, liver, and kidney, chickens develop a unique articular amyloidosis when injected with <em>Enterococcus faecalis</em> [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/38,39\" class=\"abstract_t\">38,39</a>]. Transmissibility of systemic AA amyloidosis by a seeding-nucleation process (so-called amyloid-enhancing factor [AEF]) has been identified in the pathogenesis of bovine, avian, mouse, and cheetah AA amyloid [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/40\" class=\"abstract_t\">40</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Principal pathogenic factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon findings in these animal models and results in patients, the principal pathogenic factors in AA amyloidosis (<a href=\"image.htm?imageKey=RHEUM%2F116202\" class=\"graphic graphic_figure graphicRef116202 \">figure 1</a>) appear to be the following [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/1,41,42\" class=\"abstract_t\">1,41,42</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Overproduction of both high-density lipoprotein (HDL)-associated and lipid-free serum amyloid A (SAA) as a consequence of acute and chronic inflammation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Proteolytic processing of SAA to AA, with a major cleavage occurring at position 76, thereby releasing the carboxyterminal third of the molecule [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/43\" class=\"abstract_t\">43</a>]. The in vitro demonstration of internalization of SAA by macrophages, followed by intracellular proteolysis, and later by release of amyloidogenic peptides into the extracellular space [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/44\" class=\"abstract_t\">44</a>], suggests that these events precede fibril formation. However, there is still uncertainty about the order of events in vivo [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intrinsic fibrillogenic properties of subsequences of the molecule, particularly involving the aminoterminal end [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/45,46\" class=\"abstract_t\">45,46</a>].</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Increased synthesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is an increased synthesis of SAA with inflammation due to elevated levels of proinflammatory cytokines. With rheumatoid arthritis, for example, this increase in cytokine levels correlates with synovitis, which, in turn, may stimulate synoviocytes to produce SAA [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/11,24,30,47\" class=\"abstract_t\">11,24,30,47</a>]. These events lead to elevated levels in joint fluid relative to serum [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/30\" class=\"abstract_t\">30</a>]. In addition, SAA may directly potentiate rheumatoid inflammation via the induction of matrix metalloproteinases (MMP1 and MMP3) by synovial cells and chondrocytes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/30,32,48\" class=\"abstract_t\">30,32,48</a>].</p><p>The importance of increased SAA synthesis has been demonstrated by the correlation between the serum SAA concentration and disease course in patients with established AA amyloidosis. This was illustrated in a report of 80 patients with AA amyloid (mostly due to juvenile idiopathic arthritis or to rheumatoid arthritis) who were prospectively followed for a median of four years; the systemic amyloid load was assessed by yearly serum amyloid P component (SAP) scintigraphy [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/49\" class=\"abstract_t\">49</a>]. The following findings were noted (see <a href=\"topic.htm?path=treatment-of-aa-secondary-amyloidosis\" class=\"medical medical_review\">&quot;Treatment of AA (secondary) amyloidosis&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Forty-two patients had median serum SAA concentration within the reference range (&lt;10 <span class=\"nowrap\">mg/L);</span> amyloid deposits regressed in 25 and stabilized in 14. Among patients with renal disease at baseline, proteinuria typically fell while the serum creatinine concentration was either stable or improved. Two patients who required dialysis remained on dialysis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The outcomes were variable in the other patients. However, among those in whom the serum SAA was persistently above 50 <span class=\"nowrap\">mg/L,</span> the amyloid load usually increased and organ function deteriorated. In one patient who underwent renal transplantation, proteinuria and renal amyloid deposits recurred within 36 months.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Amyloid deposition increased rapidly in patients with relapse of the underlying inflammatory disease. This observation is consistent with an underlying susceptibility to amyloidosis.</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Processing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All forms of AA amyloidosis are associated with increased levels of SAA in blood [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/50\" class=\"abstract_t\">50</a>]. In rheumatoid arthritis, however, SAA levels are increased in patients both with and without amyloidosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/51\" class=\"abstract_t\">51</a>]. This indicates that additional factors (perhaps genetic and environmental) must be involved in pathogenesis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/52,53\" class=\"abstract_t\">52,53</a>], a feature of pathogenesis underscored by the variable incidence of AA amyloidosis complicating hereditary autoinflammatory disorders [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/54\" class=\"abstract_t\">54</a>]. Other factors include aberrant degradation of SAA to AA protein [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/55\" class=\"abstract_t\">55</a>] and the accumulation of proteolytic cleavage products in blood <span class=\"nowrap\">and/or</span> tissue [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/56\" class=\"abstract_t\">56</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Intrinsic properties</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The type and size of the fragments that are formed may also determine both the amyloidogenic potential and the site of tissue deposition [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/57,58\" class=\"abstract_t\">57,58</a>]. Biochemical analysis suggests that smaller fragments are more likely to deposit in the glomeruli, while larger fragments may preferentially deposit in the blood vessels [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/58\" class=\"abstract_t\">58</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Accelerated deposition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In murine models of amyloidosis, the deposition phase of disease can be greatly accelerated by injection of AEF, an activity that is probably due to the AA fibrils, peptides, and oligomers that provide a template for amyloid deposition and that is transmissible between animals [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/1,40,59,60\" class=\"abstract_t\">1,40,59,60</a>]. The relevance of these observations to the role of SAA in inflammation and the induction of AA amyloid in susceptible individuals with inflammatory diseases remains to be determined [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/40,61\" class=\"abstract_t\">40,61</a>].</p><p class=\"headingAnchor\" id=\"H10817717\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Amyloidosis is a general term that refers to the predominantly extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) derived from any of more than 30 diverse serum proteins; these proteins have little in common with regard to their primary structure or metabolism. The fibrils have a predominantly antiparallel beta-pleated sheet configuration; they can be identified on biopsy specimens by tinctorial properties that result from the binding of specific dyes, such as Congo red. All forms of amyloidosis are characterized by codeposition of other substances, and cofactors may play a role in amyloid formation. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant. SAA proteins may function to increase the affinity of high-density lipoproteins (HDLs) for macrophages and adipocytes during the acute phase response. SAA binds specifically to several ligands, including cholesterol, HDL, calcium, laminin, and <span class=\"nowrap\">heparin/heparan</span> sulfate. (See <a href=\"#H2\" class=\"local\">'Serum amyloid A protein'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Common causes of AA amyloidosis are rheumatoid arthritis, chronic infections (particularly in underdeveloped countries), and autoinflammatory disorders. (See <a href=\"#H6\" class=\"local\">'Pathogenesis of AA amyloidosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The principal pathogenic factors in AA amyloidosis include overproduction of both HDL-associated and lipid-free SAA in both blood and tissue as a consequence of acute and chronic inflammation; proteolytic processing of SAA to AA, which releases the carboxyterminal third of the molecule and which may involve internalization of SAA by macrophages, intracellular proteolysis, and release of amyloidogenic peptides into the extracellular space; and intrinsic fibrillogenic properties of the molecule (<a href=\"image.htm?imageKey=RHEUM%2F116202\" class=\"graphic graphic_figure graphicRef116202 \">figure 1</a>). (See <a href=\"#H7\" class=\"local\">'Principal pathogenic factors'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/1\" class=\"nounderline abstract_t\">Westermark GT, F&auml;ndrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 2015; 10:321.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/2\" class=\"nounderline abstract_t\">Pinney JH, Lachmann HJ. Systemic AA amyloidosis. Subcell Biochem 2012; 65:541.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/3\" class=\"nounderline abstract_t\">Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016; 23:209.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/4\" class=\"nounderline abstract_t\">Frame NM, Gursky O. Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks. FEBS Lett 2016; 590:866.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/5\" class=\"nounderline abstract_t\">Saraiva MJ. Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev Mol Med 2002; 4:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/6\" class=\"nounderline abstract_t\">Gallo G, Wisniewski T, Choi-Miura NH, et al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145:526.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/7\" class=\"nounderline abstract_t\">Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 2007; 14:21.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/8\" class=\"nounderline abstract_t\">Husby G, Stenstad T, Magnus JH, et al. Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 1994; 70:2.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/9\" class=\"nounderline abstract_t\">Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995; 92:4299.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/10\" class=\"nounderline abstract_t\">Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 2012; 19:5.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/11\" class=\"nounderline abstract_t\">O'Hara R, Murphy EP, Whitehead AS, et al. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004; 50:1788.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/12\" class=\"nounderline abstract_t\">Thorn CF, Lu ZY, Whitehead AS. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 2004; 59:152.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/13\" class=\"nounderline abstract_t\">Ray A, Shakya A, Kumar D, et al. Inflammation-responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis. J Immunol 2006; 177:2601.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/14\" class=\"nounderline abstract_t\">Sun L, Ye RD. Serum amyloid A1: Structure, function and gene polymorphism. Gene 2016; 583:48.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/15\" class=\"nounderline abstract_t\">Takase H, Tanaka M, Yamamoto A, et al. Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A. Amyloid 2016; 23:67.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/16\" class=\"nounderline abstract_t\">Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 1999; 6:67.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/17\" class=\"nounderline abstract_t\">Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009; 61:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/18\" class=\"nounderline abstract_t\">van der Hilst JC, Yamada T, Op den Camp HJ, et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford) 2008; 47:1651.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/19\" class=\"nounderline abstract_t\">Migita K, Agematsu K, Masumoto J, et al. The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population. PLoS One 2013; 8:e55227.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/20\" class=\"nounderline abstract_t\">van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007; 18:147.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/21\" class=\"nounderline abstract_t\">Poitou C, Divoux A, Faty A, et al. Role of serum amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. J Clin Endocrinol Metab 2009; 94:1810.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/22\" class=\"nounderline abstract_t\">Ancsin JB, Kisilevsky R. Characterization of high affinity binding between laminin and the acute-phase protein, serum amyloid A. J Biol Chem 1997; 272:406.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/23\" class=\"nounderline abstract_t\">Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 2006; 108:1751.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/24\" class=\"nounderline abstract_t\">Mullan RH, Bresnihan B, Golden-Mason L, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006; 54:105.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/25\" class=\"nounderline abstract_t\">Lee HY, Kim SD, Shim JW, et al. LL-37 inhibits serum amyloid A-induced IL-8 production in human neutrophils. Exp Mol Med 2009; 41:325.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/26\" class=\"nounderline abstract_t\">He RL, Zhou J, Hanson CZ, et al. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113:429.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/27\" class=\"nounderline abstract_t\">Urieli-Shoval S, Shubinsky G, Linke RP, et al. Adhesion of human platelets to serum amyloid A. Blood 2002; 99:1224.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/28\" class=\"nounderline abstract_t\">Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. J Leukoc Biol 2015; 98:923.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/29\" class=\"nounderline abstract_t\">Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999; 274:7172.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/30\" class=\"nounderline abstract_t\">Vallon R, Freuler F, Desta-Tsedu N, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001; 166:2801.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/31\" class=\"nounderline abstract_t\">Migita K, Koga T, Torigoshi T, et al. Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes. Rheumatology (Oxford) 2009; 48:741.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/32\" class=\"nounderline abstract_t\">Connolly M, Mullan RH, McCormick J, et al. Acute-phase serum amyloid A regulates tumor necrosis factor &alpha; and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum 2012; 64:1035.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/33\" class=\"nounderline abstract_t\">Connolly M, Rooney PR, McGarry T, et al. Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. Ann Rheum Dis 2016; 75:1392.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/34\" class=\"nounderline abstract_t\">Migita K, Koga T, Komori A, et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol 2011; 38:2309.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/35\" class=\"nounderline abstract_t\">Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/36\" class=\"nounderline abstract_t\">Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997-2012. Mt Sinai J Med 2012; 79:749.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/37\" class=\"nounderline abstract_t\">Gruys E, Snel FW. Animal models for reactive amyloidosis. Baillieres Clin Rheumatol 1994; 8:599.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/38\" class=\"nounderline abstract_t\">Landman WJ. Amyloid arthropathy in chickens. Vet Q 1999; 21:78.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/39\" class=\"nounderline abstract_t\">Sevimli A, Misirlio&#287;lu D, Ya&#287;ci A, et al. The role of chicken IL-1beta, IL-6 and TNF-alpha in the occurrence of amyloid arthropathy. Vet Res Commun 2008; 32:499.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/40\" class=\"nounderline abstract_t\">Murakami T, Ishiguro N, Higuchi K. Transmission of systemic AA amyloidosis in animals. Vet Pathol 2014; 51:363.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/41\" class=\"nounderline abstract_t\">Grateau G. Musculoskeletal disorders in secondary amyloidosis and hereditary fevers. Best Pract Res Clin Rheumatol 2003; 17:929.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/42\" class=\"nounderline abstract_t\">van der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorldJournal 2011; 11:641.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/43\" class=\"nounderline abstract_t\">R&ouml;cken C, Menard R, B&uuml;hling F, et al. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis 2005; 64:808.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/44\" class=\"nounderline abstract_t\">Kinkley SM, Bagshaw WL, Tam SP, Kisilevsky R. The path of murine serum amyloid A through peritoneal macrophages. Amyloid 2006; 13:123.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/45\" class=\"nounderline abstract_t\">Westermark GT, Engstr&ouml;m U, Westermark P. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 1992; 182:27.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/46\" class=\"nounderline abstract_t\">Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD. Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1994; 1226:323.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/47\" class=\"nounderline abstract_t\">Ray A, Schatten H, Ray BK. Activation of Sp1 and its functional co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression. J Biol Chem 1999; 274:4300.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/48\" class=\"nounderline abstract_t\">Lee HY, Kim MK, Park KS, et al. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun 2005; 330:989.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/49\" class=\"nounderline abstract_t\">Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/50\" class=\"nounderline abstract_t\">Gertz MA, Skinner M, Sipe JD, et al. Serum amyloid A protein and C-reactive protein in systemic amyloidosis. Clin Exp Rheumatol 1985; 3:317.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/51\" class=\"nounderline abstract_t\">De Beer FC, Mallya RK, Fagan EA, et al. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2:231.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/52\" class=\"nounderline abstract_t\">Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006; 16:294.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/53\" class=\"nounderline abstract_t\">Utku U, Dilek M, Akpolat I, et al. SAA1 alpha/alpha alleles in Beh&ccedil;et's disease related amyloidosis. Clin Rheumatol 2007; 26:927.</a></li><li class=\"breakAll\">Ombrello AK, Aksentijevich I. AA amyloidosis. In: Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Pickens MM (Ed), Springer, 2012. p.31.</li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/55\" class=\"nounderline abstract_t\">Kluve-Beckerman B, Liepnieks JJ, Wang L, Benson MD. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol 1999; 155:123.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/56\" class=\"nounderline abstract_t\">Migita K, Eguchi K, Tsukada T, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75:371.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/57\" class=\"nounderline abstract_t\">Westermark GT, Westermark P, Sletten K. Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab Invest 1987; 57:57.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/58\" class=\"nounderline abstract_t\">Westermark GT, Sletten K, Westermark P. Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 1989; 30:605.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/59\" class=\"nounderline abstract_t\">Senthilkumar S, Chang E, Jayakumar R. Diffusible amyloid oligomers trigger systemic amyloidosis in mice. Biochem J 2008; 415:207.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/60\" class=\"nounderline abstract_t\">Westermark GT, Westermark P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett 2009; 583:2685.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-aa-amyloidosis/abstract/61\" class=\"nounderline abstract_t\">Gorevic PD. Amyloid and inflammation. Proc Natl Acad Sci U S A 2013; 110:16291.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5619 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10817717\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2391684817\" id=\"outline-link-H2391684817\">AMYLOID PRECURSORS AND AMYLOIDOGENESIS</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">SERUM AMYLOID A PROTEIN</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Types</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Possible function</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Ligands</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">PATHOGENESIS OF AA AMYLOIDOSIS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Principal pathogenic factors</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Increased synthesis</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Processing</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Intrinsic properties</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Accelerated deposition</a></li></ul></li></ul></li><li><a href=\"#H10817717\" id=\"outline-link-H10817717\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"RHEUM/5619|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/116202\" class=\"graphic graphic_figure\">- Pathogenesis of AA amyloidosis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-phase-reactants\" class=\"medical medical_review\">Acute phase reactants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-diagnosis-of-aa-amyloidosis-and-relation-to-rheumatic-diseases\" class=\"medical medical_review\">Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dialysis-related-amyloidosis\" class=\"medical medical_review\">Dialysis-related amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-factors-in-the-amyloid-diseases\" class=\"medical medical_review\">Genetic factors in the amyloid diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-amyloidosis\" class=\"medical medical_review\">Overview of amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-immunoglobulin-light-chain-al-amyloidosis-and-light-and-heavy-chain-deposition-diseases\" class=\"medical medical_review\">Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-aa-secondary-amyloidosis\" class=\"medical medical_review\">Treatment of AA (secondary) amyloidosis</a></li></ul></div></div>","javascript":null}